COR
Cencora
$271.28
▼ 0.2%Updated Jun 22, 7:15 PM ET
▼ Down 8.4% over the last 12 months
Market Cap
$52.89B
P/E
20.75x
Forward P/E (est.)
14.82x
ROE
115.9%
Revenue Growth
6.0%
EPS Growth
51.3%
Profit Margin
0.8%
FCF Yield
4.7%
Debt / Equity
5.08x
ROIC
13.0%
Interest Coverage
—
Current Ratio
0.95x
Dividend Yield
0.9%
Implied Growth (rev. DCF)
2.8%
Rating Score
52/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what COR's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. COR trades near $271.28, below its 50-day average ($286.85) and 200-day average ($324.96). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 65 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. COR's is $5.91 (~2.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month COR found buyers near $261.29 (support) and sellers near $284.93 (resistance); its 52-week range is $244.82–$377.54. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Cencora (COR) is a large-cap company in the Health Care Distributors industry, part of the Health Care sector of the S&P 500, with a market value around $52.89B.
In its latest reported year it generated about $321.33B in revenue and $1.55B in net profit.
Our model rates COR Neutral (52/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
10.7%
Revenue moved from $213.99B in 2021 to $321.33B in 2025, a 10.7% compound annual growth rate. The most recent year grew a steady 6.0% year over year. Slower, mature growth is common for established businesses.
Gross Margin
3.6%
Operating Margin
0.8%
Net Margin
0.5%
ROE
115.9%
Cencora keeps about 0.8% of each sales dollar as net profit, with a 3.6% gross margin and 0.8% operating margin. Return on equity is 115.9% and return on invested capital about 13.0%. Thin margins leave less cushion if costs rise.
Total Debt
$12.39B
Net Debt
$10.21B
Net Debt / EBITDA
3.88x
Debt / Equity
5.08x
Leverage: debt-to-equity is 5.1x, with a current ratio of 0.9x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $12.39B of total debt against $2.18B of cash.
Operating CF
$3.88B
Free Cash Flow
$3.21B
FCF Margin
1.0%
In the latest year Cencora produced about $3.88B of operating cash flow and $3.21B of free cash flow after capital spending. That is a free-cash-flow yield of about 4.7% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
20.75x
P/S
0.17x
P/B
38.81x
EV / EBITDA
17.66x
COR trades at 20.7x trailing earnings (about 14.8x on estimated forward earnings), 0.2x sales, and 38.8x book value. Reverse-engineering today's price implies the market expects roughly 2.8% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How COR stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), COR ranks #29 of 59 by our overall rating. It trades at a discount versus the sector on earnings (20.7x P/E vs. 25.4x median) with a higher return on equity (115.9% vs. 14.9%) and slower revenue growth (6.0% vs. 7.9%).
P/E vs sector
20.7x
median 25.4x
ROE vs sector
115.9%
median 14.9%
Growth vs sector
6.0%
median 7.9%
Sector rank
#29
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$861.97 – $1,392.42
vs. $271.28 today · expected CAGR 26% – 39%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $340.61B | $361.05B | $382.71B | $405.68B | $430.02B |
| Net income | $10.22B | $10.83B | $11.48B | $12.17B | $12.90B |
| EPS | $52.52 | $55.67 | $59.01 | $62.55 | $66.31 |
| Share price (low) | $682.76 | $723.73 | $767.15 | $813.18 | $861.97 |
| Share price (high) | $1,102.92 | $1,169.10 | $1,239.25 | $1,313.60 | $1,392.42 |
| CAGR (low–high) | 152% / 307% | 63% / 108% | 41% / 66% | 32% / 48% | 26% / 39% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for COR:
- Strong return on equity (115.9%) shows capital is put to work well.
- Healthy free-cash-flow yield (~4.7%) funds buybacks and dividends.
The case against COR:
- Thin net margins (0.8%) leave little room for error.
- Elevated leverage (debt/equity 5.1x) adds financial risk.
Balance-sheet risk — debt/equity of 5.1x magnifies the impact of higher rates or weaker earnings.
Margin risk — thin profitability (0.8%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Cencora is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 20.7x earnings, which our model scores Neutral (52/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.